MX2022008648A - Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas. - Google Patents

Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.

Info

Publication number
MX2022008648A
MX2022008648A MX2022008648A MX2022008648A MX2022008648A MX 2022008648 A MX2022008648 A MX 2022008648A MX 2022008648 A MX2022008648 A MX 2022008648A MX 2022008648 A MX2022008648 A MX 2022008648A MX 2022008648 A MX2022008648 A MX 2022008648A
Authority
MX
Mexico
Prior art keywords
cell differentiation
free
stroma
stem cells
immune cells
Prior art date
Application number
MX2022008648A
Other languages
English (en)
Inventor
George Q Daley
Ran Jing
Original Assignee
The Children´S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children´S Medical Center Corp filed Critical The Children´S Medical Center Corp
Publication of MX2022008648A publication Critical patent/MX2022008648A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La tecnología descrita en la presente se dirige a métodos de diferenciación de células T sin estroma. También se describen en la presente células inmunes diferenciadas utilizando métodos sin estroma y composiciones que comprenden tales células inmunes. En algunas modalidades, las células inmunes se pueden modificar genéticamente. En algunas modalidades, las células inmunes o composiciones que comprenden las células inmunes se pueden administrar a un paciente como una terapia de reemplazo celular para tratar una condición.
MX2022008648A 2020-01-23 2021-01-22 Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas. MX2022008648A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062964857P 2020-01-23 2020-01-23
US202063025412P 2020-05-15 2020-05-15
PCT/US2021/014654 WO2021150919A1 (en) 2020-01-23 2021-01-22 Stroma-free t cell differentiation from human pluripotent stem cells

Publications (1)

Publication Number Publication Date
MX2022008648A true MX2022008648A (es) 2022-12-15

Family

ID=76992791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008648A MX2022008648A (es) 2020-01-23 2021-01-22 Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.

Country Status (10)

Country Link
US (1) US20230073449A1 (es)
EP (1) EP4093857A4 (es)
JP (1) JP2023511408A (es)
KR (1) KR20220130158A (es)
CN (1) CN115397974A (es)
AU (1) AU2021211713A1 (es)
CA (1) CA3165346A1 (es)
IL (1) IL294715A (es)
MX (1) MX2022008648A (es)
WO (1) WO2021150919A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023076554A1 (en) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for promoting in vitro maturation of cells
CN114350608B (zh) * 2022-01-27 2024-05-28 昭泰英基生物医药（香港）有限公司 一种诱导t细胞重编程为类nk细胞的组合物及其应用
WO2024020365A1 (en) * 2022-07-18 2024-01-25 The Children's Medical Center Corporation Methods of t cell differentiation and compositions thereof
WO2024050534A2 (en) * 2022-09-01 2024-03-07 Regents Of The University Of Minnesota In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same
CN116445408B (zh) * 2023-05-22 2024-02-02 呈诺再生医学科技(北京)有限公司 LSD1抑制剂在促进iPSC向HSC分化和HSC干性维持中的应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US6103522A (en) 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20090217403A1 (en) 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
WO2007002358A1 (en) 2005-06-23 2007-01-04 Mount Sinai School Of Medicine Of New York University Cardiomyocyte cell populations
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
WO2008101272A1 (en) 2007-02-21 2008-08-28 Women's And Children's Health Research Institute Inc Method for obtaining treg-cells
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
US20100021437A1 (en) 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
WO2009155334A1 (en) 2008-06-20 2009-12-23 Escape Therapeutics, Inc. Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same
JP5340265B2 (ja) 2008-06-27 2013-11-13 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JP5553178B2 (ja) 2008-07-31 2014-07-16 国立大学法人岐阜大学 効率的な人工多能性幹細胞の樹立方法
US10047346B2 (en) 2008-08-08 2018-08-14 Mayo Foundation For Medical Education And Research Method of treating heart tissue using induced pluripotent stem cells
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010030947A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing t cells
WO2010050626A1 (en) 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
CA2742622C (en) 2008-11-07 2018-02-27 Juan Carlos Zuniga-Pfluecker Human progenitor t-cells
WO2010111409A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Pluripotent stem cells
WO2010115052A2 (en) 2009-04-03 2010-10-07 The Mclean Hospital Corporation Induced pluripotent stem cells
CN101580816B (zh) 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
WO2010137746A1 (en) 2009-05-29 2010-12-02 Kyoto University Method for producing induced pluripotent stem cells and method for culturing the same
US9005975B2 (en) 2009-05-29 2015-04-14 Kyoto University Method for selecting clone of induced pluripotent stem cells
CA2952805C (en) 2009-06-05 2021-06-01 Cellular Dynamics International, Inc. Reprogramming t cells and hematopoietic cells
EP2443231A4 (en) 2009-06-19 2013-02-27 Salk Inst For Biological Studi GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM UMBILICAL BLOOD
US20110027881A1 (en) 2009-07-31 2011-02-03 St. Marianna University School Of Medicine Production method of immune cells
KR101774206B1 (ko) 2009-08-07 2017-09-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
US9005976B2 (en) 2009-09-01 2015-04-14 Kyoto University Selection method of induced pluripotent stem cells
US20120263689A1 (en) 2009-09-10 2012-10-18 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
WO2011037301A1 (ko) 2009-09-22 2011-03-31 서울대학교병원 성체세포로부터 만능줄기세포를 유도하는 방법 및 그 방법에 의해 제조된 만능줄기세포
JP5773393B2 (ja) 2009-09-24 2015-09-02 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
AU2010312291A1 (en) 2009-10-29 2012-06-21 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
WO2011068962A1 (en) 2009-12-03 2011-06-09 The University Of Utah Research Foundation Methods for generating t lymphocytes from hematopoietic stem cells
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JP5765746B2 (ja) 2010-02-16 2015-08-19 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN102884188A (zh) 2010-02-18 2013-01-16 国立大学法人大阪大学 诱导性多能干细胞的制备方法
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
AU2011241514A1 (en) 2010-04-16 2012-12-06 Dnavec Corporation Method for producing induced pluripotent stem cells
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2012021867A2 (en) 2010-08-13 2012-02-16 The Johns Hopkins University A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors
WO2012027266A2 (en) 2010-08-24 2012-03-01 New York University Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells
PT3012268T (pt) 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Recetores de antigénio quimérico com uma região de charneira otimizada
US9447408B2 (en) 2010-09-14 2016-09-20 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2627342B1 (en) 2010-10-14 2016-08-24 University Of Central Florida Research Foundation, Inc. Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
KR20230133410A (ko) 2010-12-09 2023-09-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
CN102559587A (zh) 2010-12-16 2012-07-11 中国科学院上海药物研究所 诱导性多能干细胞的制备方法以及用于制备诱导性多能干细胞的培养基
US9250230B2 (en) 2011-02-01 2016-02-02 Shi V. Liu Using induced pluripotent stem cells for screening anti-neoplastic agents
US9132152B2 (en) 2011-02-10 2015-09-15 The Regents Of The University Of California Compositions and methods for generating induced pluripotent stem cells
KR101334404B1 (ko) 2011-04-28 2013-12-12 포항공과대학교 산학협력단 배아줄기세포 유래의 인공 마이크로베시클을 이용한 역분화 유도만능줄기세포의 제조방법
JP6388537B2 (ja) 2011-07-21 2018-09-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 患者由来の人工多能性幹細胞由来の心筋細胞および使用方法
WO2013028702A1 (en) 2011-08-22 2013-02-28 Mayo Foundation For Medical Education And Research Methods and materials for obtaining induced pluripotent stem cells
US9347042B2 (en) 2011-10-06 2016-05-24 Keio University Method for producing corneal endothelial cell
WO2013069661A1 (ja) 2011-11-08 2013-05-16 国立大学法人名古屋大学 iPS細胞由来血管前駆細胞シート及びその作製方法
JP6344821B2 (ja) 2011-11-21 2018-06-20 ユニバーシティ・ヘルス・ネットワーク 造血前駆体の集団および造血前駆体のための幹細胞を富化する方法
US20130157365A1 (en) 2011-12-20 2013-06-20 Advanced Technologies And Regenerative Medicine, Llc Induced pluripotent stem cells from human umbilical cord tissue-derived cells
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US9341625B2 (en) 2012-05-16 2016-05-17 Becton, Dickinson And Company Cell-surface signatures for isolating neurons from cell cultures derived from pluripotent stem cells
US20140037599A1 (en) 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency
EP2904103B8 (en) 2012-10-01 2020-03-11 Taipei Veterans General Hospital Method for preparing induced pluripotent stem cells and its applications
EP3825401A1 (en) 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP4279588A3 (en) 2012-12-12 2024-01-17 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
PL2956175T3 (pl) 2013-02-15 2018-05-30 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
DK2981607T3 (da) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
TW201631152A (zh) 2014-12-29 2016-09-01 諾華公司 製造嵌合抗原受體－表現細胞之方法
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
AU2016316033B2 (en) 2015-09-04 2022-03-03 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
CN109153975A (zh) 2015-12-28 2019-01-04 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
MX2019006286A (es) 2016-12-03 2020-02-07 Juno Therapeutics Inc Metodos para determinar la dosificacion en la terapia celular.
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car
WO2018165228A1 (en) 2017-03-08 2018-09-13 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
SG11202003177RA (en) 2017-10-25 2020-05-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells

Also Published As

Publication number Publication date
IL294715A (en) 2022-09-01
AU2021211713A1 (en) 2022-08-25
KR20220130158A (ko) 2022-09-26
EP4093857A1 (en) 2022-11-30
WO2021150919A1 (en) 2021-07-29
CA3165346A1 (en) 2021-07-29
EP4093857A4 (en) 2024-02-21
CN115397974A (zh) 2022-11-25
JP2023511408A (ja) 2023-03-17
US20230073449A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
MX2022008648A (es) Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.
BRPI0516969A (pt) método de preparar uma composição terapêutica, composição terapêutica, e, método de tratar um paciente humano sofrendo de hematopoiese deficiente
RU2012104650A (ru) Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
MX2023001831A (es) Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
CN103520082A (zh) 一种含有表皮生长因子的抗衰老组合物及其制备方法
Pokrovskaya et al. Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach
MX340185B (es) Células precursoras cd27 1 derivadas de médula ósea para reparación cardíaca.
KR20120095022A (ko) 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
MX2023004125A (es) Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
CN101791283A (zh) 一种可消除妊娠纹和疤痕的化妆品
Abdel-Sayed et al. Cell therapies for skin regeneration: An overview of 40 years of experience in burn units
WO2022187682A3 (en) Stroma-free nk cell differentiation from human pluripotent stem cells
Godic The role of stem cells in anti-aging medicine
Wang et al. Photosynthetic biomaterials: applications of photosynthesis in algae as oxygenerator in biomedical therapies
CN106701670A (zh) 一种增强间充质干细胞分泌生物活性因子能力及培养液中活性因子的提取方法
Zielins et al. Therapeutic applications of human adipose-derived stromal cells for soft tissue reconstruction
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
CN109864964B (zh) 一种包含干细胞的抗衰老组合物及其应用
Ma et al. Cell-assisted lipotransfer in the clinical treatment of facial soft tissue deformity
ZA202307198B (en) Lyophilized mesenchymal stem cells
CN107951825A (zh) 一种含有枸杞干细胞提取物的祛斑护肤品及其制备方法